Tanomastat

Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models[1][2][3].

Product Specifications

CAS Number

[179545-77-8]

Product Name Alternative

BAY 12-9566

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tanomastat.html

Purity

99.7

Solubility

DMSO : 25 mg/mL (ultrasonic; warming)

Smiles

ClC1=CC=C(C2=CC=C(C(C[C@H](CSC3=CC=CC=C3)C(O)=O)=O)C=C2)C=C1

Molecular Formula

C23H19ClO3S

Molecular Weight

410.91

Precautions

H302, H312, H332

References & Citations

[1]Leung D, et al. Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43 (3) :305-41.|[2]Gatto C, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999 Nov;5 (11) :3603-7.|[3]Nozaki S, et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancerorthotopic model. Clin Exp Metastasis. 2003;20 (5) :407-12.